Effects of High-dose Atorvastatin Pretreatment in Patients with ST-segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Cardiac Magnetic Resonance Study.
10.3346/jkms.2015.30.4.435
- Author:
Eun Kyoung KIM
1
;
Joo Yong HAHN
;
Young Bin SONG
;
Sung A CHANG
;
Jin Ho CHOI
;
Seung Hyuk CHOI
;
Sang Chol LEE
;
Yeon Hyeon CHOE
;
Sang Hoon LEE
;
Hyeon Cheol GWON
Author Information
1. Division of Cardiology, Department of Medicine, Heart Vascular Stroke Institute, Cardiovascular Imaging Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. jyhahn@skku.edu
- Publication Type:Original Article ; Multicenter Study ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
- Keywords:
Atorvastatin;
Myocardial Infarction;
Percutaneous Coronary Intervention
- MeSH:
Adult;
Aged;
Atorvastatin Calcium/*pharmacology;
Electrocardiography;
Female;
Humans;
Hydroxymethylglutaryl-CoA Reductase Inhibitors/*pharmacology;
Image Enhancement;
*Magnetic Resonance Imaging;
Male;
Middle Aged;
Myocardial Infarction/pathology/*therapy;
Myocardium/*pathology;
*Percutaneous Coronary Intervention;
Prospective Studies
- From:Journal of Korean Medical Science
2015;30(4):435-441
- CountryRepublic of Korea
- Language:English
-
Abstract:
It is uncertain that atorvastatin pretreatment can reduce myocardial damage in patients undergoing primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI). The aim of this study was to investigate the effects of atorvastatin pretreatment on infarct size measured by contrast-enhanced magnetic resonance imaging (CE-MRI) in STEMI patients. Patients undergoing primary PCI for STEMI within 12 hr after symptom onset were randomized to an atorvastatin group (n = 30, 80 mg before PCI and for 5 days after PCI) or a control group (n = 37, 10 mg daily after PCI). The primary end point was infarct size evaluated as the volume of delayed hyperenhancement by CE-MRI within 14 days after the index event. The median infarct size was 19% (IQR 11.1%-31.4%) in the atorvastatin group vs. 16.3% (7.2%-27.2%) in the control group (P = 0.27). The myocardial salvage index (37.1% [26.9%-58.7%] vs. 46.9% [39.9-52.4], P = 0.46) and area of microvascular obstruction (1.1% [0%-2.0%] vs. 0.7% [0%-1.8%], P = 0.37) did not differ significantly between the groups. Frequency of the hemorrhagic and transmural infarctions was not significantly different in the 2 groups. Pretreatment with a high-dose atorvastatin followed by further treatment for 5 days in STEMI patients undergoing primary PCI failed to reduce the extent of myocardial damage or improve myocardial salvage.
